Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
Open accessAbstract
Interferon-γ (IFN-γ)-mediated adaptive resistance is one major barrier to improving immunotherapy in solid tumors. However, the mechanisms are not completely understood. Here, we report that IFN-γ promotes nuclear translocation and phase separation of YAP after anti-PD-1 therapy in tumor cells. Hydrophobic interactions of the YAP coiled-coil domain mediate droplet initiation, and weak interactions of the intrinsically disordered region in the C terminus promote droplet formation. YAP partitions with the transcription factor TEAD4, the histone acetyltransferase EP300, and Mediator1 and forms transcriptional hubs for maximizing target gene transcriptions, independent of the canonical STAT1-IRF1 transcription program. Disruption of YAP phase separation reduced tumor growth, enhanced immune response, and sensitized tumor cells to anti-PD-1 therapy. YAP activity is negatively correlated with patient outcome. Our study indicates that YAP mediates the IFN-γ pro-tumor effect through its nuclear phase separation and suggests that YAP can be used as a predictive biomarker and target of anti-PD-1 combination therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PD-L1 induces immune evasion by targeting PD-1 on activated T cells, resulting in T cell exhaustion.
“induces immune evasion by targeting its ligand, programmed cell death 1 (PD-1) on activated T cells, resulting in T cell exhaustion1–4.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [2]
PD-L1 is widely expressed in various malignancies.
“Programmed death ligand 1 (PD-L1, namely CD274) is widely expressed in various malignancies”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [2]
The citation lists haven’t been fetched yet
References 71 · Cited by 250
- Authors
- Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., Yang, Y., Xu, S., Guo, W., Zhang, X., Shi, M., Peng, H., Luo, X., Zhang, H., Zhang, L., Li, Y., Yang, X.-P., & Sun, S.
- Affiliations
- Huazhong University of Science and Technology (CN)
- Tongji Hospital (CN)
- Corresponding author
- Sun, Shuguo
- ORCID
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 81
- Issue
- 6
- Pages
- 1216-1230.e9
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W3133105567
- Cited by
- 250
- References
- 71
- Citations by year
- 2026: 31 · 2025: 66 · 2024: 55 · 2023: 48 · 2022: 36 · 2021: 14
- FWCI
- 20.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 382 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Molecular Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- interferon-gamma, YAP, phase separation, anti-PD-1 therapy, adaptive resistance, TEAD4, EP300, coiled-coil domain, intrinsically disordered regions, transcriptional hubs, antitumor immunity, predictive biomarkers, combination therapy
- MeSH terms
- A549 Cells, Immune Checkpoint Inhibitors, YAP-Signaling Proteins, Animals, Humans, Immunotherapy, Interferon-gamma, Neoplasms, Experimental, Transcription Factors, Biomarkers, Tumor, Mice, Knockout, Drug Resistance, Neoplasm, Adaptor Proteins, Signal Transducing, Mice, HEK293 Cells, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review